2 news items
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting
ADVM
25 Apr 24
undue reliance on these forward-looking statements. Actual results and the timing of events could differ materially from those anticipated
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
ADVM
18 Mar 24
related expense, lower material production and bioanalytics, lower stock-based compensation expense, lower license fees, and lower outside research
- Prev
- 1
- Next